We have analyzed the structures, relative organization, and activities of binding sites for nuclear factors in the duck hepatitis B virus (duck HBV) enhancer. DNase I footprinting analysis and mobility shift assays demonstrate that this enhancer of 192 bp contains at least three binding sites for transcription factors: one for hepatocyte-adipocyte C/EBP, a second for the liver-specific transactivator hepatocyte nuclear factor 1 HNF-1, and a third for a factor, called F3, which binds to a DNA sequence bearing some resemblance to that for the ubiquitous factor EF-C. Analysis of transcriptional activity reveals that oligonucleotides corresponding to the individual binding sites, inserted upstream from a heterologous promoter, display very weak enhancer activity, whereas the enhancer encompassing these three sites displays very high activity. Analysis of duck HBV enhancer mutants indicates that the deletion of any of these sites leads to a modification of transcriptional enhancer activity. The hepatocyte nuclear factor 1 binding site is crucial, since an internal deletion of 14 bp abolishes the activity. The C/EBP site can act as repressor, and the F3 site is required for full activity. Comparative analysis reveals that the nuclear factors are similar to those bound to the human HBV enhancer but that the organization of their binding sites in the duck HBV enhancer is different.
Duck hepatitis B virus (DHBV) is the most divergent member of the hepadnavirus group with respect to structure and genetic organization of the genome (23) as well as biological properties. The encapsidated DHBV molecules are mostly fully double-stranded DNA, whereas they are partially single stranded for the mammalian hepadnaviruses.
DHBV lacks the transactivator X gene and infects in vivo not only the liver but also the kidney, pancreas, and spleen (17) , with very few pathological consequences (15) . In general, the DHBV genome does not integrate into the cellular genome. These characteristics of DHBV contrast sharply with those of human hepatitis B virus (HBV). Comparative study of the organization and function of cis-regulatory sequences that govern the genetic expression of DHBV and HBV should provide an understanding of their respective biological properties.
In HBV, two enhancers, enhancer I and enhancer II, have been characterized. Enhancer I, located in the DNA polymerase gene between nucleotides (nt) 991 and 1243, is active in a wide variety of tissues (11, 33) . Several known nuclear factors have been shown to bind to this enhancer. Among them are APlIjun-fos; C/EBP, which binds to several binding sites (11, 27) ; nuclear factor 1 (NF-1), which binds to three sites (3); and EF-C, which binds to only one site (26) .
Enhancer I is also the transactivation target of the X gene product (20, 32) . Enhancer II, located in the X gene between nt 1645 and 1803, was recently identified and is functionally liver specific (34, 36) . It binds the C/EBP-like proteins at two sites whose cooperation is indispensable for enhancer functions in vitro (37) . Other binding sites, for transactivating factors such as hepatocyte nuclear factor 1 (HNF-1), have been located upstream of the major surface antigen promoter region (8, 28) .
We have previously described the identification of a strong enhancer element upstream from the pregenomic RNA start site of the DHBV genome (10) . We present here an analysis * Corresponding author.
of the structures, relative organization, and functions of the binding sites of the DHBV enhancer for C/EBP, HNF-1, and a factor called F3 which bears some resemblance to the binding site for EF-C of HBV. We also compare the genetic organization of the DHBV enhancer with that of the HBV enhancer.
MATERIALS AND METHODS
Plasmid constructions. Plasmid DH23-1 contains the AluINcoI 192-bp fragment (nt 2159 to 2351) upstream the thymidine kinase promoter followed by a chloramphenicol acetyltransferase (CAT) gene and the simian virus 40 polyadenylation signal of pBLCAT2 (22) . DHO7, DHO5, and DHO3 are pBLCAT2 containing oligonucleotides inserted upstream from the thymidine kinase promoter. DHO7 was constructed with oligonucleotide Fl (5'-TCGACCACATG GCGCAATATCCCATATCCCGCGGG-3'), DHO5 was constructed with oligonucleotide F2 (5'-GATCCGTCGACTT TAGCCAAGATAATGATTAAACCGCGGG-3'), and DHO3 was constructed with oligonucleotide F3 (5'-TCGACCCACGT TGTCTCTlTATCTGATTCAACTlrTCCGCGGG-3'). Consensus oligonucleotides C/EBP (5'-ATJCAATTGGGCAATC AG-3') (1), HNF1 (5'-TGTGGTTAATGATCTACAGTTA-3') (30) , and EF-C (5'-CCCCGTTGCCCGGCAACGGGC-3') (26) (10) . In hepatic cells, this 192-bp enhancer element potentiates a marked increased activity from the heterologous thymidine kinase promoter in an orientation-independent manner and at proximal as well as distal locations (10, 31) . To better define the function of this enhancer, we searched for regulating transcriptional factors that would bind to the DHBV enhancer region by DNase I footprinting assays. For this purpose, crude nuclear extracts from HepG2 cells were incubated with the 330-bp AluI-TaqI (nt 2159 to 2489) DNA fragment which contains the 192-bp enhancer element. This fragment was end labeled on either the coding or noncoding strand. Complexes were digested with DNase I, and the products were analyzed on a 6% acrylamide denaturing gel.
As shown in Fig. 1 , three protected regions, Fl (nt 2185 to 2192), F2 (nt 2272 to 2294), and F3 (nt 2296 to 2321), were observed. Fl and F2 were detected on the coding strand, and F3 was detected on the noncoding strand.
Computer analysis of the nucleotide sequence of each protected region reveals that the Fl site contains a sequence, 5'-TGGCGCAAT-3', perfectly matching the C/EBP (2) con- (Fig. 2) . The F2 site (5'-AGATAATGATTAAAC-3') matches the HNF-1 (29) consensus site (G/A)GTTAATNATTAAC(C/A) except for the nt 3 and 14, where adenosine is in place of a thymidine and a cytosine, respectively. The F3 site bears only some resemblance to the EF-C binding site, harboring two GIJG and CAAC inverted repeats but with a spacing of 14 bp instead of 5 bp in the C element of polyomavirus or HBV (26) .
From these experiments, we conclude that the DHBV enhancer contains at least three binding sites for HepG2 Figure 3A, lane 2) . With the F2 probe, two complexes are detected; one is strong and slow migrating, the other is slight and fast migrating (Fig. 3B, lane 2) . With the F3 probe, three complexes are detected (Fig. 3C, lane 2) .
To test binding specificity, competition experiments using 5-to 100-fold molar excesses of cold competitors were performed.
As shown in Fig. 3A , the two complexes observed with the Fl probe are dissociated equally well when the cold Fl competitor is added. With the F2 probe, only the slowmigrating, strong complex is displaced when the cold F2 competitor is added. It appears that the faster-migrating complex is not relevant to the DHBV enhancer, since this DNA sequence does not inhibit the formation of the fastermigrating F2 complex. Each complex observed with the F3 probe is competed for when the cold F3 competitor is added. The slow-migrating complex (open arrow in Fig. 3C ) is less sensitive to the competitor. The Fl probe is competed against with the cold Fl but not the cold F2 or F3 competitor (Fig. 3A) ; the F2 probe is competed against with the cold F2 but not the Fl or F3 competitor (Fig. 3B) ; the F3 probe is competed against with the cold F3 but not the Fl or F2 competitor (Fig. 3C) .
We conclude from these experiments that the binding of HepG2 nuclear factors to the protected regions Fl, F2, and F3 is specific.
To verify that the nuclear factors bound to each individually protected region also bind to the whole enhancer, we performed competition experiments using either the Fl, F2, or F3 labeled probe and the 192-bp enhancer fragment (nt 2159 to 2351) as the cold competitor. Figure 4 shows that each binding site is competed for by the 192-bp enhancer fragment at a 20-to 100-fold molar excess. These results indicate that each binding site is fully operational in the whole enhancer.
Examination of each of the protected regions reveals that the Fl site contains a sequence matching the C/EBP consensus site. The F2 site matches the HNF-1 binding site from the rat albumin proximal element, and the F3 site shares homology only with the two GTTG and CAAC inverted repeats of the EF-C binding site. To identify formally each of these putative binding sites and to compare them with related sites in the HBV genome, we used mobility shift assays with competitor oligonucleotides derived from the consensus site for C/EBP as described by Bakker and Parker (2) and from the well-studied rat albumin proximal element for HNF-1 (30) and from EF-C (nt 1147 to 1170) (26) .
As shown in Fig. 4A the C/EBP oligonucleotide at a 100-fold molar excess competes, although not completely, for HepG2 nuclear factors with the Fl-derived labeled oligonucleotide (compare lane 2 with lanes 7 to 9). The heat stability of the factors involved in the two complexes is evident (Fig. 4A, lane 3 The EF-C oligonucleotide derived from HBV does not compete, even at a 100-fold molar excess, with the F3-derived labeled oligonucleotide (Fig. 4C, lanes 6 to 8) .
From these results, we conclude that Fl contains a binding site for a C/EBP-related factor and that the F2 site contains a binding site for an HNF-1-related factor. For F3, we observed a complete absence of competition of the F3 site with the EF-C oligonucleotides; therefore, although the DNA sequence bears some resemblance to that of EF-C, it is unlikely that F3 is related to EF-C. It must be noted that the F3 probe is competed against with the F3 cold competitor as well as with the cold 192-bp DHBV enhancer fragment. (12, 14) . To correlate the binding of these nuclear factors with DHBV enhancer function, we tested the enhancing activity of each of these three binding sites. For this purpose, each oligonucleotides was cloned in the sense orientation in the polylinker of plasmid pBLCAT2. Plasmids DHO7, DHO5, and DHO3 contain a C/EBP-related binding site (Fl), an HNF-1-related binding site (F2), and binding site F3, respectively. These clones were used to transfect the human hepatoblastoma cell line HepG2, and the amount of CAT activity found in extracts of these cells was determined (Fig. 6) . For the three clones, very low activity is detected. In sharp contrast, the entire DHBV enhancer element of 192 bp (plasmid DH23-1) shows an 88-fold-higher activity. This result indicates that each factor exhibits a poor transactivating efficiency.
Activity of DHBV enhancer mutants with deletions in the C/EBP, HNF-1, and F3 binding sites. To test whether there could be a synergy between these factors that would account for the very high activity of the DHBV enhancer, in contrast with the weak activity of each individual binding site, we deleted each binding site of the 192-bp enhancer. For this purpose, deletions at chosen sites, using exonuclease BAL 31, were performed. The extent of each deletion was examined by sequence analysis. Among the deletion mutants, we retained three that were interesting with respect to deletion of the Fl, F2, or F3 binding site (Fig. 6A) . The C/EBP, HNF-1, and F3 binding sites were deleted in mutants DH2211, DH2277, and DH2295, respectively. The activities of these deletion mutants are shown in Fig.  6 . In HepG2 cells, the activities of plasmids DH2211, DH2277, and DH2295 varied and were quite different from the activity of the wild-type enhancer (plasmid DH23-1). The enhancer activity was increased (from 62 to 79%) when the C/EBP binding site was deleted (plasmid DH2211) and decreased from 62 to 35% when the F3 binding site was deleted (plasmid DH2295). The main difference concerns DH2277, which has an internal 14-bp deletion of the HNF-1 binding site and in which the activity was almost completely abolished (from 62 to 5%).
From these experiments, we conclude that the HNF-1 binding site is crucial for the enhancer activity and that sequences including the C/EBP and F3 sites modulate the activity. The C/EBP site seems to act as an inhibitory element, and the F3 site is required for full activity.
DISCUSSION
We analyzed the fine structure of the enhancer upstream from the pregenomic RNA start site of the DHBV genome and demonstrated that this strong enhancer of 192 bp contains at least three binding sites, one for C/EBP, a second for HNF-1, and a third for F3, a factor which bears some resemblance to EF-C.
C/EBP binds to enhancer sequences of several viral enhancers and CAAT sequences (18) . It is involved in transcriptional control of the albumin gene in hepatocytes and of adipocyte-specific genes (5) . The specific consensus sequence T(T/G)NNGC(A/C/G)A(T/G) for C/EBP is also recognized by several proteins, such as IL-6-DBP, Ig/EBP-1, and NF-IL-6. These factors belong to the same multigenic family, since their basic and leucine zipper regions are very homologous (1, 19) . C/EBP can form a dimer with any of these factors or with the recently discovered proteins CRP1 and CRP3 (35) . The combination of these factors may result in the formation of transcriptional complexes with different properties as suggested for C/EBP-,B and C/EBP-8, which are differentially expressed during adipocyte differentiation (5) .
In HBV, C/EBP binds to two sites (nt 1180 to 1204) in enhancer I and can function as a transcriptional activator at low concentrations and as a repressor at high concentrations. This binding seems to proceed in a hierarchic and cooperative manner and in some circumstances might involve other sites within enhancer I (11) . More recently, it was shown that enhancer II contains nucleotide sequences, box a and box 1B, related to the C/EBP binding site (37) .
In the DHBV enhancer, we found by DNase I footprinting assays that the protected region Fl is 100% homologous to the C/EBP binding site. A synthesized oligonucleotide corresponding to this C/EBP sequence binds specifically to nuclear extracts of the HepG2 cells, and two DNA-protein complexes are observed in mobility shift assays ( Fig. 3 and  4) . The heat stability of the factors involved in the two complexes is high. Figure 4A , lane 3, shows two DNAprotein complexes, observed after treatment at 95°C for 15 min (7, 37) . Given the fact that the Fl site is 100% homologous to the C/EBP consensus site and that the C/EBP oligonucleotide competes, although not completely, with Fl, the recognized site on Fl likely binds C/EBP. The presence of two bands in mobility shift assays could involve oligomer- (Fig. 6) .
HNF EF-C is a ubiquitous factor present in nuclear extracts of murine and human cells. It binds to the C element of the polyomavirus enhancer and to HBV enhancer I (25, 26) . The binding site contains two inverted repeats (GTTG and CAAC) separated by five nucleotides. Mutagenesis studies indicate that EF-C is probably stabilized by dimerization (26) . The F3 binding site of DHBV shares homology with the EF-C consensus sequence, harboring the two inverted repeats but with a different spacing. This spacing has been shown to be essential for HBV enhancer function. Competition experiments in mobility shift assays indicate that the F3 site is competed for completely with a whole DHBV enhancer fragment but not at all with the EF-C of the HBV enhancer. Ostapchuck et al. (26) have shown that the HBV EF-C sequences do not compete for the HBV enhancer I after insertion of nucleotides between the two inverted repeats. Therefore, it is possible that another factor binds to the DHBV F3 binding site. Indeed, in the case of hormone receptors, it has been reported that the same sequence of inverted repeats binds different factors according to the length of the spacing (24) . Deletion of the F3 site of the DHBV enhancer leads to a decrease in activity of 50%. As for the C/EBP and HNF-1 sites, the F3 site has a very weak transcriptional activity.
The DHBV enhancer and HBV enhancer I are located in the coding region of the DNA polymerase gene. At least two and perhaps three binding sites, which we describe here for the DHBV enhancer, have been described for HBV. The main difference between DHBV and HBV concerns the number of binding sites and their organization (Fig. 7) .
Concerning the number of binding sites in the DHBV enhancer, we found a single binding site for each nuclear factor. The C/EBP and HNF-1 sites are on the same coding strand, and the F3 site is located on the noncoding strand. In (36), the large surface protein promoter (8, 28) , and the major surface antigen regulatory region (29) .
the HBV enhancer I, at least two binding sites for C/EBP, three for NF-1, and one for EF-C have been described. It must be noted that the HNF-1 binding site for HBV is located upstream of the S promoter and therefore very distant (-1,000 nt) from enhancer I, whereas it is located within the enhancer between the C/EBP and F3 binding sites for DHBV.
It has been reported for HBV that C/EBP can bind to multiple sites and acts as an activator at low concentrations or as a repressor at high concentrations (11) . In this study, we have not tested the concentration effect of C/EBP and therefore cannot exclude the presence of other C/EBP binding sites which can counterbalance or reverse the activity of the DHBV enhancer. Furthermore, we cannot exclude the binding of other factors involving specific experimental conditions for their detection.
Concerning the organization of the binding sites, in DHBV, the C/EBP site is located at the 5' end of the enhancer between nt 2185 and 2192, HNF-1 site occupies the central region at nt 2272 to 2294 and, the F3 site is located at nt 2296 to 2321 in the 3' end. Thus, these three sites in DHBV do not overlap. In HBV, one C/EBP site is located between the EF-C and NF-la sites, and the NF-lb site overlaps the C/EBP and EF-C sites. Figure 7 summarizes this organization.
In conclusion, we have demonstrated that the DHBV enhancer contains at least three binding sites for nuclear factors: one for C/EBP, a second for HNF-1, and a third for a factor called F3. The deletion of any of these sites leads to a decrease in transcriptional enhancer activity. The mechanism of activation seems to occur via a synergy between HNF-1, which plays a central role, and F3 and C/EBP. The F3 site modulates positively, since it is required for full activity, and the C/EBP site modulates negatively, as its deletion increases transcriptional activity. The factors that bind to the HBV and DHBV sites are similar, but the HBV and DHBV enhancers differ in genetic organization. This difference may contribute to the differential genetic expression and biological properties of HBV and DHBV.
